vTv Therapeutics Inc (NASDAQ:VTVT) has been assigned a consensus recommendation of “Buy” from the six brokerages that are currently covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $16.00.
A number of equities analysts recently weighed in on VTVT shares. Zacks Investment Research raised vTv Therapeutics from a “hold” rating to a “buy” rating and set a $6.50 price target on the stock in a research note on Saturday, September 30th. Citigroup reaffirmed an “add” rating on shares of vTv Therapeutics in a research note on Wednesday, November 8th. Stifel Nicolaus reaffirmed a “buy” rating and set a $12.00 target price on shares of vTv Therapeutics in a research note on Friday, November 3rd. Finally, Canaccord Genuity set a $15.00 target price on vTv Therapeutics and gave the company a “buy” rating in a research note on Thursday, December 21st.
In other news, Director Paul G. Savas purchased 15,000 shares of the stock in a transaction that occurred on Thursday, December 7th. The stock was acquired at an average price of $4.56 per share, with a total value of $68,400.00. Following the purchase, the director now owns 81,781 shares in the company, valued at approximately $372,921.36. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.80% of the company’s stock.
vTv Therapeutics (NASDAQ:VTVT) opened at $4.05 on Thursday. The firm has a market capitalization of $135.19 and a PE ratio of -2.47. vTv Therapeutics has a 12 month low of $3.57 and a 12 month high of $8.09.
TRADEMARK VIOLATION WARNING: “vTv Therapeutics Inc (VTVT) Given Average Rating of “Buy” by Brokerages” was first published by Community Financial News and is the property of of Community Financial News. If you are accessing this article on another domain, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The correct version of this article can be read at https://www.com-unik.info/2017/12/28/vtv-therapeutics-inc-vtvt-given-average-rating-of-buy-by-brokerages.html.
vTv Therapeutics Company Profile
vTv Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer’s disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial.
What are top analysts saying about vTv Therapeutics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for vTv Therapeutics and related companies.